{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:38:56Z","timestamp":1770989936447,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T00:00:00Z","timestamp":1512432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","award":["268904"],"award-info":[{"award-number":["268904"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.vaccine.2017.10.079","type":"journal-article","created":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T00:46:22Z","timestamp":1512175582000},"page":"313-321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes"],"prefix":"10.1016","volume":"36","author":[{"given":"Annette","family":"von Delft","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy A.","family":"Donnison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Louren\u00e7o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Hutchings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin E.","family":"Mullarkey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver G.","family":"Pybus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Klenerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senthil","family":"Chinnakannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.10.079_b0005","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.10.079_b0010","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.10.079_b0015","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jhep.2013.05.019","article-title":"Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C","volume":"59","author":"Camm\u00e0","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.vaccine.2017.10.079_b0020","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/jac\/dkq157","article-title":"Antiviral therapy for hepatitis C: why are so few patients being treated?","volume":"65","author":"Volk","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.vaccine.2017.10.079_b0025","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0168-8278(13)60053-7","article-title":"HCV treatment rate in select european countries in 2004\u20132010","volume":"1","author":"Razavi","year":"2013","journal-title":"J Hepatol Supplement"},{"key":"10.1016\/j.vaccine.2017.10.079_b0030","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.05.010","article-title":"Detection of a sexually transmitted Hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man","author":"Franco","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2017.10.079_b0035","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.10.079_b0040","unstructured":"WHO. WHO | Global hepatitis report. WHO (2017). http:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/; 2017 [accessed 23.09.17]."},{"key":"10.1016\/j.vaccine.2017.10.079_b0045","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","author":"Messina","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2017.10.079_b0050","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.immuni.2006.09.005","article-title":"Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses","volume":"25","author":"Yewdell","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2017.10.079_b0055","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.23096","article-title":"Degree of cross-genotype reactivity of hepatitis C virus-specific CD8+ T cells directed against NS3","volume":"50","author":"Giugliano","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2017.10.079_b0060","article-title":"The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design","author":"von Delft","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.vaccine.2017.10.079_b0065","doi-asserted-by":"crossref","unstructured":"Barnes E, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012; 4: 115ra1.","DOI":"10.1126\/scitranslmed.3003155"},{"key":"10.1016\/j.vaccine.2017.10.079_b0070","doi-asserted-by":"crossref","unstructured":"Swadling L, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 2014; 6: 261ra153.","DOI":"10.1126\/scitranslmed.3009185"},{"key":"10.1016\/j.vaccine.2017.10.079_b0075","article-title":"Cross-reactivity of hepatitis C virus-specific vaccine induced T cells at immunodominant epitopes","author":"Kelly","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2017.10.079_b0080","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1517\/13543776.2012.673589","article-title":"Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities","volume":"22","author":"Roohvand","year":"2012","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.vaccine.2017.10.079_b0085","unstructured":"Health Protection Agency. Hepatitis C in the UK: 2013 report. http:\/\/www.hpa.org.uk\/Publications\/InfectiousDiseases\/BloodBorneInfections\/HepatitisCInTheUK\/1307HepatitisCintheUK2013report\/; 2013 [accessed 10.03.14]."},{"key":"10.1016\/j.vaccine.2017.10.079_b0090","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment Web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2017.10.079_b0095","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2017.10.079_b0100","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/nbt1197-1280","article-title":"A protein particle vaccine containing multiple malaria epitopes","volume":"15","author":"Gilbert","year":"1997","journal-title":"Nat Biotech"},{"key":"10.1016\/j.vaccine.2017.10.079_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciq015","article-title":"Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA\u2212NP+M1","volume":"52","author":"Berthoud","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.079_b0110","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1128\/JVI.72.2.1497-1503.1998","article-title":"Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage","volume":"72","author":"Andr\u00e9","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.10.079_b0115","doi-asserted-by":"crossref","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.10.079_b0120","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2172-9-8","article-title":"Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research","volume":"9","author":"Lin","year":"2008","journal-title":"BMC Immunol"},{"key":"10.1016\/j.vaccine.2017.10.079_b0125","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1186\/1471-2105-9-S12-S22","article-title":"Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research","volume":"9","author":"Lin","year":"2008","journal-title":"BMC Bioinform"},{"key":"10.1016\/j.vaccine.2017.10.079_b0130","doi-asserted-by":"crossref","unstructured":"Jespersen MC, Peters B, Nielsen M, Marcatili P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res 2017; 45: W24\u2013W29.","DOI":"10.1093\/nar\/gkx346"},{"key":"10.1016\/j.vaccine.2017.10.079_b0135","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.coviro.2015.04.001","article-title":"Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design","volume":"11","author":"Kong","year":"2015","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2017.10.079_b0140","article-title":"Spontaneous control of HCV is associated with the expression of HLA-B*57 and preservation of targeted epitopes","author":"Kim","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2017.10.079_b0145","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1136\/gut.2010.228403","article-title":"Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection","volume":"60","author":"Fitzmaurice","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.vaccine.2017.10.079_b0150","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.23275","article-title":"Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope","volume":"51","author":"Neumann-Haefelin","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2017.10.079_b0155","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s002510050595","article-title":"SYFPEITHI: database for MHC ligands and peptide motifs","volume":"50","author":"Rammensee","year":"1999","journal-title":"Immunogenetics"},{"key":"10.1016\/j.vaccine.2017.10.079_b0160","doi-asserted-by":"crossref","first-page":"e1000107","DOI":"10.1371\/journal.pcbi.1000107","article-title":"Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan","volume":"4","author":"Nielsen","year":"2008","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.vaccine.2017.10.079_b0165","doi-asserted-by":"crossref","first-page":"8125","DOI":"10.1093\/nar\/15.20.8125","article-title":"An analysis of 5\u2019-noncoding sequences from 699 vertebrate messenger RNAs","volume":"15","author":"Kozak","year":"1987","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.vaccine.2017.10.079_b0180","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1371\/journal.pone.0000984","article-title":"Design and pre-clinical evaluation of a universal HIV-1 vaccine","volume":"2","author":"L\u00e9tourneau","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.10.079_b0185","article-title":"Expanded classification of hepatitis C Virus into 7 genotypes and 67 Subtypes: updated criteria and assignment web resource","author":"Smith","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2017.10.079_b0190","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.immuni.2012.11.022","article-title":"Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design","volume":"38","author":"Ferguson","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2017.10.079_b0195","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.tim.2014.12.008","article-title":"HIV-1 adaptation to HLA: a window into virus-host immune interactions","volume":"23","author":"Carlson","year":"2015","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.vaccine.2017.10.079_b0200","doi-asserted-by":"crossref","first-page":"e38028","DOI":"10.1371\/journal.pone.0038028","article-title":"A meta-analysis of the existing knowledge of immunoreactivity against hepatitis C virus (HCV)","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.10.079_b0205","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/hep.23319","article-title":"Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection","volume":"51","author":"Fuller","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2017.10.079_b0210","doi-asserted-by":"crossref","first-page":"12584","DOI":"10.1128\/JVI.76.24.12584-12595.2002","article-title":"Broad specificity of virus-specific CD4+ T-Helper-cell responses in resolved hepatitis C virus infection","volume":"76","author":"Day","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.10.079_b0215","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1126\/science.1088774","article-title":"HCV persistence and immune evasion in the absence of memory T cell help","volume":"302","author":"Grakoui","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.10.079_b0220","doi-asserted-by":"crossref","first-page":"e1002041","DOI":"10.1371\/journal.ppat.1002041","article-title":"Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges","volume":"7","author":"Im","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2017.10.079_b0225","article-title":"Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1","author":"Borthwick","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2017.10.079_b0230","first-page":"141","article-title":"A systematic bioinformatics approach for selection of epitope-based vaccine targets","volume":"244","author":"Khan","year":"2006","journal-title":"CellImmunol"},{"key":"10.1016\/j.vaccine.2017.10.079_b0235","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1016\/j.vaccine.2013.06.068","article-title":"Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB\/c mice","volume":"31","author":"Ondondo","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.079_b0240","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0000000000000047","article-title":"DNA\/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge","author":"Koopman","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2017.10.079_b0245","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1016\/j.vaccine.2006.03.009","article-title":"Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects","volume":"24","author":"Firbas","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.079_b0250","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2174\/092986609788681788","article-title":"Polytope DNA vaccine development against hepatitis C virus: a streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB\/c mice","volume":"16","author":"Memarnejadian","year":"2009","journal-title":"Protein Pept Lett"},{"key":"10.1016\/j.vaccine.2017.10.079_b0255","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11262-009-0417-3","article-title":"Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB\/c mice","volume":"40","author":"Arashkia","year":"2010","journal-title":"Virus Genes"},{"key":"10.1016\/j.vaccine.2017.10.079_b0260","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.4049\/jimmunol.1103008","article-title":"Immunogenicity and cross-reactivity of a representative ancestral sequence in hepatitis C virus infection","volume":"188","author":"Burke","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.10.079_b0265","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nm1461","article-title":"Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants","volume":"13","author":"Fischer","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2017.10.079_b0270","doi-asserted-by":"crossref","first-page":"8300","DOI":"10.1128\/JVI.00114-09","article-title":"T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces","volume":"83","author":"Korber","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.10.079_b0275","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nm.2089","article-title":"Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys","volume":"16","author":"Barouch","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2017.10.079_b0280","article-title":"Increased valency of conserved-mosaic vaccines enhances the breadth and depth of epitope recognition","author":"Abdul-Jawad","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2017.10.079_b0285","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/CVI.00605-12","article-title":"Hepatitis C genotype 1 mosaic vaccines are immunogenic in mice and induce stronger T-cell responses than natural strains","volume":"20","author":"Yusim","year":"2013","journal-title":"Clin Vaccine Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17314871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17314871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:23:58Z","timestamp":1759400638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17314871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0264410X17314871"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.079","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}